A fully automated system utilizing a liquid handler and an online solid-phase extraction (SPE) device coupled with liquid chromatography-tandem mass spectrometry (LC-MS-MS) was designed to process, detect, and quantify benzoylecgonine (BZE), meta-hydroxybenzoylecgonine (m-OH BZE), parahydroxybenzoylecgonine (p-OH BZE), and norbenzoylecgonine (nor-BZE) metabolites in human urine. The method was linear for BZE, m-OH BZE, and p-OH BZE from 1.2 to 10,000 ng/mL with limits of detection (LOD) and quantification (LOQ) of 1.2 ng/mL. Nor-BZE was linear from 5 to 10,000 ng/mL with an LOD and LOQ of 1.2 and 5 ng/mL, respectively. The intrarun precision measured as the coefficient of variation of 10 replicates of a 100 ng/mL control was less than 2.6%, and the interrun precision for 5 replicates of the same control across 8 batches was less than 4.8% for all analytes. No assay interference was noted from controls containing cocaine, cocaethylene, and ecgonine methyl ester. Excellent data concordance (R 2 > 0.994) was found for direct comparison of the automated SPE-LC-MS-MS procedure and an existing gas chromatography-MS procedure using 94 human urine samples previously determined to be positive for BZE. The automated specimen handling and SPE procedure, when compared to the traditional extraction schema, eliminates the human factors of specimen handling, processing, extraction, and derivatization, thereby reducing labor costs and rework resulting from batch handling issues, and may reduce the number of fume hoods required in the laboratory.
Introduction
Cocaine abuse continues to be a problem in the United States. In 2006, approximately 7.7% of college students and 15.2% of young adults (ages [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] reported the use of cocaine (1) . The use of cocaine is associated with significant physical and mental health impairment and is inconsistent with the military readiness and mission achievement requirements of the United States Armed Forces. Therefore, cocaine is among the panel of illicit substances for the Department of Defense Drug Abuse Testing Program (2, 3) . Benzoylecgonine (BZE), a major cocaine metabolite, is analyzed to provide evidence that the service member ingested cocaine due in part to its longer elimination half life (4) , and BZE comprises 35-54% of total cocaine metabolites eliminated in the urine (5, 6) . Because BZE can be formed in vitro, the presence of enzymatic cocaine metabolites believed to arise solely via in vivo metabolism can offer additional evidence that cocaine was ingested (7) (8) (9) . Therefore, the specific metabolites considered in this study were BZE, para-hydroxybenzoylecgonine (p-OH BZE), meta-hydroxybenzoylecgonine (m-OH BZE), and norbenzoylecgonine (nor-BZE).
Prior to the development of solid-phase extraction (SPE) methodology, the detection of illicit drug use was performed by liquid-liquid partition with analysis primarily via gas chromatography-mass spectrometry (GC-MS) (10) . Although GC-MS analysis is considered the analytical gold standard for forensic drug urine analysis, multiple preparatory steps for the analysis of a particular drug metabolite are required, including extraction of the sample and derivatization of the metabolite to render the analyte volatile for analysis. In addition, most of the preparatory steps require the use of chemical fume hoods for the safe removal of hazardous vapors. With the advent of SPE technology, the extraction time and quantity of solvents used to perform the extraction process have decreased.
The use of automated SPE coupled with GC-MS analysis has been reported, but the methods do not address the requirement for automated derivatization of the analyte (11) . Recently, manually operated positive-pressure manifold procedures have been developed which increase sample throughput, but they also lack an automated derivatization procedure (12) . Other more recent improvements in the processing of urinalysis samples has been reported through the use of fast GC-MS, a method that decreases analysis time by employing a 220 V GC oven to provide faster temperature ramps (13) .
Liquid chromatography-tandem mass spectrometry (LC-MS-MS) is a viable technique for the complete automation of analysis for illicit drugs and their metabolites because it does not require that the analyte be derivatized. Detection of illicit drug metabolites by LC-MS-MS, which utilizes direct injection of the urine onto the LC column, has been reported (14) (15) (16) . Although direct injection improves analysis time by eliminating the extraction and derivatization steps, analytical column life may be reduced because of urine matrix contamination. Attempts to extend column life by using a pre-column to extract and then divert the analyte to an analytical LC-MS column have been reported (17) . However, the reuse of precolumns increases the potential for analyte carryover from one sample to the next, which may cast doubt on the reliability and accuracy of the results during legal proceedings. The use of online SPE systems that have single-use SPE cartridge exchange for every injection eliminates the cartridge as a source of crosscontamination between samples (18). In summary, several time-saving procedures have been developed for the analysis of illicit substances, but no single method has simultaneously improved sample handling, tracking, automation, and analysis.
This report describes a totally automated online SPE system directly coupled to an LC-MS-MS for the detection and quantification of BZE, p-OH BZE, m-OH BZE, and nor-BZE. This procedure utilizes single-use SPE cartridge exchange for every sample, thereby eliminating the cartridge as a source of crosscontamination between samples, extending analytical column life, decreasing MS-MS maintenance, and enhancing the forensic integrity of the analysis through the use of automated sample handling. Additionally, an automated liquid handler was used to pipette the addition of all human urine samples, controls, calibrators, and internal standards, and to prepare all samples required for validation of the method linearity, accuracy, precision, carryover, and interferences from other cocaine metabolites.
A set of 94 authentic human urine samples and a set of 15 open proficiency samples previously determined to contain BZE were analyzed in parallel with the LC-MS-MS method and the laboratory's current GC-MS method for comparison.
Materials and Methods

Chemicals and reagents
High-performance liquid chromatography (HPLC)-grade methanol, acetonitrile, and water were acquired from Fisher Scientific (Pittsburgh, PA). Reagent-grade formic acid, puriss potassium phosphate monobasic, puriss potassium phosphate dibasic anhydrous, N,N-dimethylformamide dipropyl acetal, and ammonium hydroxide were obtained from Sigma-Aldrich (St. Louis, MO). HPLC-grade ethyl acetate and iso-octane, 0.1 M HCl, glacial acetic acid, concentrated sulfuric acid, 1.0 N sodium hydroxide, and potassium carbonate were purchased from J.T. Baker (Phillipsburg, NJ). N, N-Dimethylformamide was purchased from Omnisolv (Gibbstown, NJ).
Sample and internal standard delivery
All authentic human urine samples, controls, and standard solutions were automatically pipetted using the Tecan EVO 100 liquid handler (Tecan, Lausanne, Switzerland) ( Figure 1 ). The liquid handler pipetted ( Figure 1A) 1.0 mL of each sample, 75 µL of internal standard (final concentration = 95.7 ng/mL), and Figure 1B ). For the GC-MS and LC-MS-MS comparative study, the liquid handler pipetted 4.5 mL of authentic human urine samples, controls, or standard solutions and 300 µL of internal standard (final concentration = 93.8 ng/mL). The sample was then split into a 3.0-mL aliquot for GC-MS analysis and a 750-µL aliquot and 0.1 mL of 1.0 M acetic acid were delivered directly into ALS vials placed in the Reliance autosampler tray for SPE-LC-MS-MS analysis. The pipette tips ( Figure 1C ) are automatically replaced after each delivery of solution and the location of the samples during each step of the pipetting event is tracked by the Tecan EVO 100 liquid handler using a structured query language-based sample tracking program and bar-coded labels.
Automated SPE system
The Symbiosis Pharma (Spark Holland, Emmen, Netherlands) automated SPE system is composed of a refrigerated conditioned stacker unit (Figure 2A ), autosampler unit ( Figure  2B ), automatic cartridge extraction (ACE) unit ( Figure 2C ), and two binary HPLC pumps ( Figure 2D ). The conditioned stacker unit houses and shuttles 48-position autosampler racks loaded with pre-aliquotted samples in 13 × 32-mm ALS vials to the Reliance autosampler unit that pierces the vial septa, then withdraws and delivers the sample to the sample loop in the injection valve ( Figure 2E) . The racks are then returned to the conditioned stacker unit. The loop injector was programmed to wash both internal and external surfaces five times using 700 µL of water and 700 µL of acetonitrile, methanol, isopropanol, and water (40:40:10:10, v/v/v/v), repeating these two washes, and finally 1400 µL of water between injections to reduce the potential for carryover. The last three wash steps include a valve wash in which the autosampler valve is cycled to provide a more effective wash. The sample loop is plumbed directly into the ACE unit via the left clamp valve ( Figure 2F ) which functions to load the sample onto the SPE cartridge. Following sample extraction, the SPE cartridge is moved automatically to the elution clamp. While the elution of the initial cartridge occurs, the next cartridge is conditioned, loaded, and washed in preparation for the next analysis. This process is repeated sequentially for each sample. The ACE unit automatically records the number of uses for each SPE cartridge via radiofrequency identification chip on the SPE cartridge tray. Complete firmware control of the Symbiosis Pharma and Waters Quattro Micro MS-MS (Waters, Milford, MA) is embedded in the Waters Masslynx control software.
LC-MS-MS sample extraction
The SPE cartridges previously placed in the ACE unit were activated with 1 mL of 0.1% formic acid in acetonitrile, and conditioned with 1 mL water. For all experiments, 50 µL of sample was drawn into the autosampler loop and loaded onto the SPE cartridge using 1 mL of 2% methanol in water. The cartridge was washed with 1 mL of 2% methanol in water to remove contaminants that may shorten column life or interfere with the analysis of BZE, nor-BZE, m-OH BZE, and p-OH BZE. The SPE cartridge was eluted into the LC mobile phase using 250 µL of acetonitrile/0.1% formic acid in water (50:50, v/v). The flow rate for the SPE elution solvent, which is critical for the separation of m-OH BZE and p-OH BZE, was 0.250 µL/min.
Chromatographic parameters
Chromatographic separation of the analytes was performed using a 4.6-mm × 150-mm, 5-µm Waters Xterra C8 column. The analytical column was preceded by a 4.6 × 10-mm Waters Xterra C8 MS 5-µm guard column. The injection volume for all experiments performed was 50 µL. The mobile phase was established as 1% acetic acid in water (A) and acetonitrile (B) with a flow rate of 1.0 mL/min. The gradient was initialized using solely solution A for 2 min and then ramped from 2 to 6 min to 30% solution B. The gradient was held until 8 min and then reduced linearly to 100% A and held for 4 min (19) . The eluent was split post-column, and 350 µL/min was directed to the MS-MS for analysis.
MS-MS conditions
MS-MS detection was carried out in electrospray ionization (ESI) mode using a Quattro Micro (Waters Micromass) triple-quadrupole MS. Table I shows the MS parameters for data acquisition of the metabolites. All MS-MS parameters were determined by manually tuning to obtain the best possible multiple reaction monitoring (MRM) response.
Standards and controls
Stock methanolic solutions of BZE, m-OH BZE, nor-BZE, and BZE-d 3 (1 mg/mL) were purchased from Cerilliant (Round Rock, TX). Stock methanolic solutions of p-OH BZE, m-OH BZE-d 3 , and p-OH BZE-d 3 (100 µg/mL) were purchased from ElSohly Laboratories (Oxford, MS). Analyte concentrations for samples and controls were determined by multipoint calibration by spiking certified drug-free urine with 10, 50, 100, 500, and 1000 ng/mL each of BZE, m-OH BZE, p-OH BZE, and nor-BZE. The multiconstituent internal standard solution was prepared in methanol at a concentration of 1500 ng/mL each of BZE-d 3 , m-OH BZE-d 3 , and p-OH BZE-d 3 . The internal standard for quantification of nor-BZE for the LC-MS-MS method was BZE-d 3 . Each analytical batch contained a negative control prepared from drug-free certified urine and a positive quality control sample containing 125 ng/mL each of BZE, m-OH BZE, p-OH BZE, and nor-BZE in certified drug-free negative urine.
GC-MS extraction and analysis
After the addition of 100 µL of a 1.0 M phosphate buffer (pH 6.0), the samples were extracted using a Speedisk ® 48-position positive-pressure manifold (SPEWare, San Pedro, CA). The tubes were vortex mixed, centrifuged for 5 min at 1200-2000 rpm using an IEC clinical centrifuge (Thermo Fisher Scientific, Waltham, MA), and the samples poured into 3-mL Cerex (CLIN II) SPE cartridges (SPEWare). The cartridges were washed consecutively with 1.0 mL water, 1.0 mL of 0.1 M HCl, 1.0 mL methanol, and 1.0 mL ethyl acetate. The cartridges were eluted with 1.0 mL ethyl acetate, methanol, and ammonium hydroxide solution (69:29:2, v/v/v). The elutate was evaporated to dryness under dry nitrogen and the samples derivatized using 50 µL N,N-dimethylformamide dipropylacetal in 50 µL of N,Ndimethylformamide. The samples were incubated in a heating block at 110°C for 30 min. After incubation, 1.0 mL of 0.3 M sulfuric acid and 2.0 mL ethyl acetate were added to each sample. The tubes were vortex mixed and centrifuged at 1200-2000 rpm, and the organic layer was removed to waste. After the addition of 200 µL of 1.0 N NaOH, 500 µL of 1.5 M pH 9.5 carbonate buffer, and 2.0 mL iso-octane to the aqueous layer, the samples were vortex mixed and centrifuged at 1200-2000 rpm, and the aqueous layer was removed. Each sample was evaporated to dryness under dry nitrogen, reconstituted with 50 µL of ethyl acetate, and transferred to ALS vials for GC-MS analysis.
The samples were analyzed using an Agilent 6890 GC equipped with a 7683 autoinjector and a DB-XLB capillary column (15 m × 0.25 mm × 0.25-µm film thickness) coupled to a 5975 mass selective detector (MSD) (Agilent, Little Falls, DE). The injection port was maintained at 265ºC with a 25:1 split ratio using helium as the carrier gas at a column pressure of 2.0 psi. The MSD was operated in selected ion monitoring (SIM) mode using m/z 210, 331, and 272 for BZE and m/z 213 and 334 for BZE-d 3 .
Quantification of BZE in samples and controls was calculated by dividing the m/z 210/213 response factor of the sample by the m/z 210/213 response factor of the calibration curve. The qualifier ratios were m/z 331/210 and m/z 272/210 for the analyte and m/z 334/213 for the internal standard. Qualitative identification of the sample required that the retention time be within 2% and the qualifier ions abundance ratios are within 20% of the weighted average of all calibrators. Each analytical batch contained open controls at 0 and 125 ng/mL BZE. Quantifications of controls were required to be within 20% of the target concentration, and the negative controls were required to be less than the LOD for the analyte. The 100 ng/mL calibrator was reinjected at the end of each analytical run to monitor any change in instrument performance.
Results and Discussion
Initial method development of the cocaine metabolite extraction procedure was accomplished using the Spark Holland's method development tray which contains eight wideranging types of sorbents, allowing for rapid method development with a generic extraction method. The C 8 (2 mm × 10 mm) SPE cartridge was determined to be the best choice in terms of recovery and separation of the diastereomers.
The effect of pH on BZE, m-OH BZE, and nor-BZE SPE retention was minimal, but it was considerable for p-OH BZE. Under basic conditions, p-OH BZE was not retained well on the SPE cartridge. Thus, in order to retain p-OH BZE on the SPE column, 100 µL of 1.0 M acetic acid was used to buffer the sample. The acidification step was without effect on the recovery of the other three metabolites. Because the SPE eluant has an additive effect on the HPLC mobile phase, and is generally stronger (i.e., contains a greater percentage of the organic component) than the initial mobile phase conditions, it can have a pronounced effect on mobile phase composition. The optimum SPE cartridge retains the metabolites effectively but also allows elution with a minimal amount of organic solvent. This was particularly important for separation of the p-OH BZE and m-OH BZE as a strong mobile phase merges the analytes on the analytical column. The C 8 cartridge provided optimum retention of the metabolites and required only 250 µL of the acetonitrile/water, 0.1% formic acid (50:50, v/v) eluting solvent.
Observation of ion suppression was performed using postcolumn infusion of each analyte as described by Bonfiglio et al. (20) using duplicate injections of a drug-free urine matrix. There was no ion suppression noted for m-OH BZE and p-OH BZE or their isotopically labeled analogues at their respective retention times. Although ion suppression was observed for BZE, and BZE-d 3 , the effect of ion suppression is mitigated through the use of an internal standard that is isotopically labeled and coelutes with the analyte (20) . In contrast, the ion suppression effect for nor-BZE was absent, whereas the BZE-d 3 signal was suppressed at their respective retention times. Therefore, the results for nor-BZE may be overestimated by suppression of its internal standard signal. Unfortunately, isotopically labeled nor-BZE was unavailable at the time of the study. The authors acknowledge that using an isotopic analogue is the best choice of standard for electrospray ionization. Doing so would also eliminate the ESI response differences for nor-BZE and BZE-d 3 that are due to the different chemical nature of the compounds.
The MRM chromatograms of a standard containing 125 ng/mL each of BZE, nor-BZE, p-OH BZE, m-OH BZE, and their respective internal standards BZEd 3 Figure 3 . The peaks are Gaussian-shaped and resolved to baseline with all analytes eluted by 7.2 min into the analysis. Notably, the total run time for the first sample including extraction overhead was 15 min, but that overhead is only incurred for the first sample as subsequent samples are extracted during the analytical run for the prior sample. p-OH BZE, m-OH BZE, nor-BZE, and BZE were detected at approximate retention times of 6.45, 6.72, 6.96, and 7.16, respectively. Although the GC-MS analysis provides a faster BZE analysis time (i.e., BZE is resolved to baseline at approximately 3 min with a total time of 4 min), it is important to recognize that the GC-MS analysis time does not include the time required for manual preparation, extraction, and derivatization of the samples (approximately 2 h for a batch of 25 samples), all of which occurs in an automated fashion with the SPE LC-MS-MS method.
. m-OH BZE-d 3 , and p-OH BZE-d 3 as analyzed by LC-MS-MS are shown in
The LOD and LOQ for the automated SPE-LC-MS-MS method were determined by analyzing, in quintuplicate, eight concentration levels (100, 50, 25, 20, 10, 5, 2.5, 1.2 ng/mL) of samples spiked with BZE, m-OH BZE, p-OH BZE, and nor-BZE. For BZE, the LOD was set as the lowest concentration at which all replicates produced analyte qualifying ion ratios within 20% of the calibrator ratio. The LOQ was set as the lowest concentration at which the analyte qualifying ion ratios were within 20% of the calibrator determined ratios and the concentrations were within 20% of the target concentration. For the single-transition analytes (nor-BZE, p-OH BZE, and m-OH BZE), the LOD was found acceptable by having a concentration within 20% of theoretical and appropriate chromatographic parameters (i.e., correct baselines, no interfering shoulder peaks at > 10% of analyte peak height, and United States Pharmacopeia peak symmetry calculation between 0.5 and 2.0 measured at 10% of peak height). The LOQ was set by chromatographic parameters alone. The LOD and LOQ were 1.2 ng/mL for BZE, m-OH BZE, and p-OH BZE and 1.2 and 5 ng/mL for nor-BZE, respectively (Table II) . In comparison, the LOD and LOQ of the GC-MS BZE method currently used in the laboratory for production was 15 ng/mL.
The ULOL was established by analyzing, in quintuplicate, samples prepared with BZE, m-OH BZE, p-OH BZE, and nor-BZE at 10,000, 7500, 5000, 2500, 1000, and 100 ng/mL. For BZE, the ULOL was set at the highest concentration at which all replicates produced daughter ion ratios within 20% of the ratios calculated from the calibrator and concentrations were within 20% of the target concentration. For the single transition analytes, the ULOL was set using concentration and chromatographic acceptability limits as described previously. The ULOL for each of the analytes was 10,000 ng/mL (Table II) . In contrast, the ULOL of the BZE GC-MS method currently used in the laboratory for production purposes was 7500 ng/mL. Carryover limit (COL) studies were conducted using 10,000, 50,000, and 100,000 ng/mL of BZE controls each followed by three negative controls. There was no carryover observed in the three negative controls following injection of the 10,000 ng/mL BZE control. After injection of the 50,000 ng/mL BZE control, a 17 ng/mL signal was obtained, but the signal did not pass acceptability criteria for BZE ion ratio or peak symmetry. The second negative sample following the 50,000 ng/mL control was negative. The first negative control following the 100,000 ng/mL BZE control quantitated at 31 ng/mL, but did not pass acceptability criteria for ion ratio or symmetry. The second blank injection quantified at 3.3 ng/mL but lacked a qualifying ion. The third blank injection was negative. The carryover limit was determined to be 10,000 ng/mL (Table II) . The COL was not determined for m-OH BZE, p-OH BZE, and nor-BZE as these metabolites are in far lesser concentrations in authentic human urine samples (7, 9) . The precision of the automated SPE-LC-MS-MS method was assessed using intrarun and interrun precision studies. The intrarun precision was determined by analyzing 10 drug-free urine samples spiked with BZE, m-OH BZE, p-OH BZE, and nor-BZE at 100 ng/mL. The coefficient of variation (CV) for all four analytes was less than or equal to 2.6% (Table II) . The corresponding intrarun precision CV for a 100 ng/mL BZE-only standard analyzed by the GC-MS assay using single point calibration at 100 ng/mL is 0.95%. The interrun precision was determined by analyzing 40 drug-free urine samples spiked with BZE, m-OH BZE, p-OH BZE, and nor-BZE at 100 ng/mL over the course of 8 analytical runs. The CV for all four analytes was less than or equal to 4.8% (Table II) . The corresponding interrun precision (% CV = 1.7) of the GC-MS BZE only method was determined by analyzing drug-free urine samples spiked with BZE at 100 ng/mL (n = 40) over the course of 40 analytical runs.
The specificity of the SPE-LC-MS-MS method was investigated by challenging the assay with compounds structurally related to BZE. The potential interferences from ecgonine methyl ester, cocaine, and cocaethylene were analyzed at a concentration of 10,000 ng/mL alone and in the presence of 20 ng/mL of BZE and evaluated for their potential of co-eluting with and/or possessing ions common to BZE and the internal standard BZE-d 3 . None of the three compounds produced interference with the correct identification or quantitation of BZE.
A comparative study was conducted in which two different sets of samples were analyzed using the standard GC-MS method and the automated SPE-LC-MS-MS procedure. The first set consisted of 15 open proficiency samples prepared by the Armed Forces Institute of Pathology (Rockville, MD) using a pharmaceutical grade BZE drug stock and assayed across four analytical batches. The second sample set was comprised of 94 authentic human urine samples submitted under the Department of the Navy's drugs of abuse testing program and previously determined to contain BZE by GC-MS.
The concentration of BZE detected in the open proficiency set and the set of 94 authentic human urine samples ranged from 34.5 to 10,077 ng/mL (Table III) and 29.4 to 110,513 ng/mL, respectively (Table IV) . Of the set of 94 authentic human urine samples, 8 contained BZE in excess of the instruments' ULOL which were diluted and reanalyzed. Only three of the samples (11, 29 , and 48) were outside the acceptable range of a 20% difference between the two methods (Table  IV) . There was no statistical difference between the quantitative values generated for either of the sample sets assayed by the two analytical methods as related to analysis of variance and/or linear regression (Figures 4 and 5) . Although the data concordance (r 2 = 0.9767) is lower when only those samples with BZE concentrations between 50 ng/mL and 200 ng/mL are considered (Figure 5 ), the agreement of samples at the Department of Defense cutoff concentration for BZE (100 ng/mL) is consistent. As noted by other experts, there was no correlation between the amount of BZE found in human urine as compared to the other metabolites (7, 9) .
Conclusions
In this study, the newly developed automated SPE-LC-MS-MS method for the analysis of BZE and its enzymatic metabolites m-OH BZE, p-OH BZE, and nor-BZE in human urine was validated and compared to the laboratory's current GC-MS BZE-only method. Regarding assay LOD, LOQ, linearity, accuracy, and precision, the SPE-LC-MS-MS method produced comparable or better results than the GC-MS method.
The SPE-LC-MS-MS analysis combines the time savings of direct injection, the sample clean-up of pre-column extraction, and the additional forensic integrity of providing single use cartridge exchange for each sample and automated sample tracking. LC-MS-MS analysis begins immediately after the extraction of the first cartridge, eliminating the usual extraction lead time (approximately 2.0 h for a batch of 25 samples) with the GC-MS method of analysis. Subsequent cartridges are prepared during analysis of the prior cartridge, and are delivered to the elution clamp just-in-time for the next analysis. The entire automated SPE process requires approximately 5 min per sample. Should the analysis time fall below that of the SPE time, the latter (SPE) becomes the rate-limiting step.
Although the overall time required from sample pour-up through completion of analysis for the two methods was comparable, the capability of the SPE-LC-MS-MS procedure is superior due to the automated features of the system. First, the methodology requires no human manipulations of the samples from receipt of the extraction set to data reduction, and complete sample tracking with barcodes provides an extremely high level of forensic integrity. Secondly, the method provides considerable cost savings in labor overhead as technicians are freed to perform other laboratory duties. The actual technician time required for manual extraction and injection setup for the GC-MS method was 2 h for a typical batch of 25 samples. In comparison, the manual loading of reagents and trays into the liquid handler for the liquid handler and injection setup time is only 10-20 min for the SPE-LC-MS-MS method. Note that the time technicians spend waiting for laboratory equipment processing, such as incubation, centrifugation, vortex mixing, or instrument analysis time, was not included in these estimates. Third, because the automated procedure provides additional information on enzymatic cocaine metabolites, the ingestion of cocaine can be proven. Additionally, the SPE-LC-MS-MS process is inherently safer because derivatizing agents and hazardous chemicals, other than mobile phase or mobile phase modifiers, are not required, which may permit reductions in the chemical fume hood footprint of the laboratory.
In conclusion, the newly developed automated SPE-LC-MS-MS method produced comparable or better results than the GC-MS method with regards to LOD, LOQ, linearity, accuracy, and precision. Moreover, the automated sample handling features of the liquid handler unit and SPE-LC-MS-MS procedure increase the forensic integrity of the laboratory methods by eliminating manual sample processing events for the confirmation of BZE.
